– quantitative MRI – T1, T2, T2*, T2′ relaxometry, magnetization transfer, chemical exchange staturation transfer (CEST)-imaging, diffusion tensor imaging (DTI), perfusion imaging
– MR spectroscopy (H1, P31)

Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology. 2014 Jul 15;83(3):227-34. doi:10.1212/WNL.0000000000000594. Epub 2014 Jun 13. Erratum in: Neurology. 2014 Sep 16;83(12):1123. PubMed PMID: 24928118.

Hattingen E, Lückerath C, Pellikan S, Vronski D, Roth C, Knake S, Kieslich M,
Pilatus U. Frontal and thalamic changes of GABA concentration indicate
dysfunction of thalamofrontal networks in juvenile myoclonic epilepsy. Epilepsia. 2014 Jul;55(7):1030-7. doi: 10.1111/epi.12656. Epub 2014 Jun 5. PubMed PMID:24902613.

Hattingen E, Jurcoane A, Daneshvar K, Pilatus U, Mittelbronn M, Steinbach JP, Bähr O. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neuro Oncol. 2013 Oct;15(10):1395-404. doi: 10.1093/neuonc/not105. Epub 2013 Aug 7. PubMed PMID: 23925453; PubMed Central PMCID: PMC3779046.

Jurcoane A, Wagner M, Schmidt C, Mayer C, Gracien RM, Hirschmann M, Deichmann R, Volz S, Ziemann U, Hattingen E. Within-lesion differences in quantitative MRI parameters predict contrast enhancement in multiple sclerosis. J Magn Reson Imaging. 2013 Dec;38(6):1454-61. doi: 10.1002/jmri.24107. Epub 2013 Apr 1. PubMed PMID: 23554005.

Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H,
Zanella F, Hilker R. Phosphorus and proton magnetic resonance spectroscopy
demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease. Brain. 2009 Dec;132(Pt 12):3285-97. doi: 10.1093/brain/awp293. PubMed PMID: 19952056.